Teva Releases Limited Doses of Generic Version of EpiPen in U.S.
2018年11月28日 - 1:02AM
Dow Jones News
By Colin Kellaher
Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday said it
released limited doses of its generic version of Mylan N.V.'s
EpiPen 0.3-milligram injector device in the U.S.
The pharmaceutical company said the publically available
wholesale acquisition cost for the product is $300.
The U.S. Food and Drug Administration in August approved Teva's
generic version of the EpiPen device for life-threatening allergic
reactions, the most widely sold such device in the U.S.
EpiPens have been in short supply since at least May, with
problems stemming from regional supply disruptions and manufacturer
issues.
The product touched off a furor two years ago over its price
increases of 548% over about a decade to just above $600 for a
two-pack. Mylan introduced its own half-priced generic version of
the drug in 2016.
Teva said it expects an additional supply of its generic version
of the EpiPen, along with a generic version of the EpiPen Jr, will
be available next year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 27, 2018 10:47 ET (15:47 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024
